An experimental target-based platform in yeast for screening Plasmodium vivax deoxyhypusine synthase inhibitors.

Catarina Bourgard, Per Sunnerhagen, Mário Henrique Bengtson, Katlin Brauer Massirer, Elizabeth Bilsland, Fabio Trindade Maranhão Costa, Renan Vinicius de Araujo, Heloísa Monteiro do Amaral Prado, Luis Carlos Salazar-Alvarez, Cleslei Fernando Zanelli, Sayyed Jalil Mahdizadeh, Sunniva Sigurdardóttir, Angélica Hollunder Klippel, Suélen Fernandes Silva, Ievgeniia Tiukova, Leif A Eriksson, Ross D King

Journal: PLoS neglected tropical diseases 2024;18(12):e0012690

PMID: 39621767

Abstract

The enzyme deoxyhypusine synthase (DHS) catalyzes the first step in the post-translational modification of the eukaryotic translation factor 5A (eIF5A). This is the only protein known to contain the amino acid hypusine, which results from this modification. Both eIF5A and DHS are essential for cell viability in eukaryotes, and inhibiting DHS is a promising strategy to develop new therapeutic alternatives. DHS proteins from many are sufficiently different from their human orthologs for selective targeting against infectious diseases; however, no DHS inhibitor selective for parasite orthologs has previously been reported. Here, we established a yeast surrogate genetics platform to identify inhibitors of DHS from Plasmodium vivax, one of the major causative agents of malaria. We constructed genetically modified Saccharomyces cerevisiae strains expressing DHS genes from Homo sapiens (HsDHS) or P. vivax (PvDHS) in place of the endogenous DHS gene from S. cerevisiae. Compared with a HsDHS complemented strain with a different genetic background that we previously generated, this new strain background was ~60-fold more sensitive to an inhibitor of human DHS. Initially, a virtual screen using the ChEMBL-NTD database was performed. Candidate ligands were tested in growth assays using the newly generated yeast strains expressing heterologous DHS genes. Among these, two showed promise by preferentially reducing the growth of the PvDHS-expressing strain. Further, in a robotized assay, we screened 400 compounds from the Pathogen Box library using the same S. cerevisiae strains, and one compound preferentially reduced the growth of the PvDHS-expressing yeast strain. Western blot revealed that these compounds significantly reduced eIF5A hypusination in yeast. The compounds showed antiplasmodial activity in the asexual erythrocyte stage; EC50 in high nM to low μM range, and low cytotoxicity. Our study demonstrates that this yeast-based platform is suitable for identifying and verifying candidate small molecule DHS inhibitors, selective for the parasite over the human ortholog.

Copyright: © 2024 Fernandes Silva et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Address: Department of Chemistry and Molecular Biology, University of Gothenburg, Göteborg, Sweden.; Chemistry Institute, São Paulo State University - UNESP, Araraquara, São Paulo, Brazil.; Center for Medicinal Chemistry - CQMED, Center for Molecular Biology and Genetic Engineering - CBMEG, Universidade Estadual de Campinas, Campinas, São Paulo, Brazil.; Center for Medicinal Chemistry - CQMED, Center for Molecular Biology and Genetic Engineering - CBMEG, Universidade Estadual de Campinas, Campinas, São Paulo, Brazil.; School of Pharmaceutical Sciences, São Paulo State University-UNESP, Araraquara, São Paulo, Brazil.; Department of Chemistry and Molecular Biology, University of Gothenburg, Göteborg, Sweden.; Department of Life Sciences, Chalmers, Göteborg, Sweden.; Department of Chemistry and Molecular Biology, University of Gothenburg, Göteborg, Sweden.; Laboratory of Tropical Diseases, Institute of Biology, Universidade Estadual de Campinas - UNICAMP, Campinas, São Paulo, Brazil.; Laboratory of Tropical Diseases, Institute of Biology, Universidade Estadual de Campinas - UNICAMP, Campinas, São Paulo, Brazil.; Center for Medicinal Chemistry - CQMED, Center for Molecular Biology and Genetic Engineering - CBMEG, Universidade Estadual de Campinas, Campinas, São Paulo, Brazil.; Department of Structural and Functional Biology, Institute of Biology, Universidade Estadual de Campinas - UNICAMP, Campinas, São Paulo, Brazil.; Center for Medicinal Chemistry - CQMED, Center for Molecular Biology and Genetic Engineering - CBMEG, Universidade Estadual de Campinas, Campinas, São Paulo, Brazil.; Department of Biochemistry and Tissue Biology, Institute of Biology, Universidade Estadual de Campinas, Campinas, São Paulo, Brazil.; Chemistry Institute, São Paulo State University - UNESP, Araraquara, São Paulo, Brazil.; School of Pharmaceutical Sciences, São Paulo State University-UNESP, Araraquara, São Paulo, Brazil.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.